Advanced Search Results For "Ophthalmic Solutions"
Your filters
Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials.
Publication Type: Academic Journal
Source(s): Indian journal of ophthalmology [Indian J Ophthalmol] 2023 Apr; Vol. 71 (4), pp. 1304-1315.
Abstract: Dry eye disease (DED) is a common multi-factorial disease that is characterized by tear film instability. Diquafosol tetrasodium (DQS), an ophthalmic solution, has been shown to be beneficial in the treatment of DED. The goal of this study was to provi...
A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution.
Publication Type: Academic Journal
Source(s): Drugs in R&D [Drugs R D] 2023 Mar; Vol. 23 (1), pp. 43-53. Date of Electronic Publication: 2022 Dec 21.
Abstract: Background and Objective: Palovarotene, a selective retinoic acid receptor γ agonist, is under investigation for the treatment of dry eye disease. This study aimed to determine the ocular and systemic safety, tolerability and pharmacokinetics of palova...
NGF Prevents Loss of TrkA/VEGFR2 Cells, and VEGF Isoform Dysregulation in the Retina of Adult Diabetic Rats.
Publication Type: Academic Journal
Source(s): Cells [Cells] 2022 Oct 15; Vol. 11 (20). Date of Electronic Publication: 2022 Oct 15.
Abstract: Among the factors involved in diabetic retinopathy (DR), nerve growth factor (NGF) and vascular endothelial growth factor A (VEGFA) have been shown to affect both neuronal survival and vascular function, suggesting that their crosstalk might influence ...
Prediction of serious eye damage or eye irritation potential of compounds via consensus labelling models and active learning models based on uncertainty strategies.
Publication Type: Academic Journal
Source(s): Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2022 Nov; Vol. 169, pp. 113420. Date of Electronic Publication: 2022 Sep 13.
Abstract: Serious eye damage and eye irritation have been authenticated to be significant human health issues in various fields such as ophthalmic pharmaceuticals. Due to the shortcomings of traditional animal testing methods, in silico methods have advanced to ...
The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease: A Phase 1b Study.
Publication Type: Academic Journal
Source(s): Ophthalmic surgery, lasers & imaging retina [Ophthalmic Surg Lasers Imaging Retina] 2022 Oct; Vol. 53 (10), pp. 553-560. Date of Electronic Publication: 2022 Oct 01.
Abstract: Background and Objectives: To evaluate the safety, tolerability, and biological activity of a topical selective integrin inhibitor (OTT166) eyedrop administered BID for diabetic retinopathy (DR) and diabetic macular edema (DME).Study Design/materials a...
The genus decision: Potential impact on ophthalmic pharmaceuticals.
Publication Type: Editorial & Opinion
Source(s): The ocular surface [Ocul Surf] 2022 Oct; Vol. 26, pp. 342-344. Date of Electronic Publication: 2022 Aug 17.
Abstract: Competing Interests: Declaration of competing interest Gary D. Novack PhD consults with numerous pharmaceutical and medical device firms. Kristin Williams, J.D. has no disclosures.
NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.
Publication Type: Academic Journal
Source(s): American journal of ophthalmology [Am J Ophthalmol] 2023 Aug; Vol. 252, pp. 265-274. Date of Electronic Publication: 2023 Mar 21.
Abstract: Purpose: To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop for the treatment of signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).Design: Randomized, double-masked, controlle...
Ophthalmic nano-bioconjugates: critical challenges and technological advances.
Publication Type: Academic Journal
Source(s): Therapeutic delivery [Ther Deliv] 2023 Jul; Vol. 14 (7), pp. 419-441. Date of Electronic Publication: 2023 Aug 03.
Abstract: Ophthalmic disease can cause permanent loss of vision and blindness. Easy-to-administer topical and systemic treatments are preferred for treating sight-threatening disorders. Typical ocular anatomy makes topical and systemic ophthalmic drug delivery c...
Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial.
Publication Type: Academic Journal
Source(s): Drug design, development and therapy [Drug Des Devel Ther] 2022 Sep 20; Vol. 16, pp. 3183-3194. Date of Electronic Publication: 2022 Sep 20 (Print Publication: 2022).
Abstract: Purpose: To confirm the efficacy and safety of a novel ophthalmic cyclosporine A gel (CyclAGel, 0.05% CsA) in treating patients with moderate-to-severe dry eye disease (DED).Patients and Methods: The COSMO trial was a randomized, multicenter, double-ma...
γ-Cyclodextrin-based polypseudorotaxane hydrogels for ophthalmic delivery of flurbiprofen to treat anterior uveitis.
Publication Type: Academic Journal
Source(s): Carbohydrate polymers [Carbohydr Polym] 2022 Feb 01; Vol. 277, pp. 118889. Date of Electronic Publication: 2021 Nov 14.
Abstract: Anterior uveitis is a sight-threatening inflammation inside the eyes. Conventional eye drops for anti-inflammatory therapy need to be administered frequently owing to the rapid elimination and corneal barrier. To address these issues, polypseudorotaxan...